Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

Phase 1 studies with PSI-7851 in the first quarter of 2009;

-- Report interim results from INFORM-1 trial in second quarter of 2009;

-- Report interim results from 28 day add-on study with R7128 in non-responder, HCV genotype 2 and genotype 3 patients in first half of 2009;

-- Report interim results from 28 day add-on study with R7128 in treatment naive, HCV genotype 1 patients in first half of 2009;

-- Report phase 1 antiviral data with PSI-7851 in second half of 2009.

About Pharmasset

Pharmasset is a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe, among other countries. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial. Pharmasset also anticipates initiating phase 1 studies with its second generation nucleotide inhibitor for HCV, PSI-7851 in the first quarter of 2009.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    '/>"/>
SOURCE  Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...re/--BiotechfirmReplikinsLtd.,whichhasanalyzedtheH...rediction,outbreak,andprogressofthecurrentH1N1pand...irus.ThenewdatashowsthatthelethalityoftheH1N1("Swi...ingthevirus,scurrentoutbreakinthespringof2009tores...N1virus,infectivitycount,however,remainsincreased....
(Date:11/25/2009)...ire/--Reportlinker.comannouncesthatanewmarketresea...ioethanolMarketAnalysisandForecaststo2013 ,, ...anol-Market-Analysis-and-Forecasts-to-2013.html ,...013 ,, Summary ,, Thereportprovidesdetaile...dtheBrazilbioethanolmarketinparticular.Italsohelps...
(Date:11/24/2009)...New York investment bank KTA Capital,s client Neur...6.7 mil convertible note private placement with a ... was arranged by KTA Capital as Neuren,s exclusive... New York (PRWEB) November 23, 2009 -- The i...LC ("KTA Capital") has announced that it...
(Date:11/24/2009)...lth care employment grew by 29,000 jobs in Octobe...istent growth during the U.S. recession. However, ... and health systems are coming closer to having to...dministrators. , (Vocus) ...ued growing in October despite the shedding of job...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
...ards Now Online, ROCKAWAY, N.J., Oct. 1 R&D Maga...l Innovator of the Year and 43rd Annual,Scientist ...o exemplify the,ideals of R&D in academia, industr...he nomination process was facilitated online with ...rs -- chosen by the magazine,s readers.,The finali...
...Lumiphore, Inc., a,biotechnology leader in the dev...hanide technology for use in high-value applicatio...ement with Biophor Diagnostics, Inc.,Redwood City,...tic tests,for drugs of abuse., Under the agreemen...de,rights to Lumi4(TM) technology in current and f...
...ins Presidential Support for Faster Registration ..., WASHINGTON, Sept. 30 Dr. Kenneth Alibek, Presi...r. Peter M. Leitner, President of,MaxWell USA, LLC...o honor,Ukrainian President Victor Yushchenko., (...4/NETU078LOGO ), The breakfast was hosted by the...
Other Biology Technology:2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced 2Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board 2Ukrainian President Yushchenko: Pharmaceuticals 'Very Important' 2
(Date:11/26/2009)...phylococcus Aureus ) and other drug-resistant bact...asma prototype devices have been developed to offe...ktails. , Two prototype devices have been develo...n (e.g. hands and feet) in hospitals and public sp...another to shoot bacteria-killing agents into infe...
(Date:11/25/2009)... easy lives. In addition to mammalian immune syste...s called bacteriophages, viruses that kill half th...cteria and another class of microorganisms called ...such as deep-sea volcanic vents) manage just fine,...efense system that helps protect them from many vi...
(Date:11/25/2009)...Soil is the linchpin of the environment, where atm...that, many students see soil as "just dirt" a pla...educators are challenged with the task of helping ...ortance of soil in the environment. , A collabo...eachers at University of Nebraska-Lincoln, Oregon ...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3It's not just dirt! 2Sunrise to Transition from Management of EdenCare Communities 49442 1Fallopian tubes offer new stem cell source 12704 1Elephant size loopholes sustain Thai ivory trade 8912 1Elephant size loopholes sustain Thai ivory trade 8912 2
... way that had never been observed in any animal be... Biology, a Cell Press publication. The discoveryw...s that the ability to perceive circular polarized ...unication. , Mantis shrimp ventured into a new di...versity of Queensland in Australia. Also known as ...
...se is a rare, devastating illness in which nerve c... deteriorate. One form of it, Lou Gehrigs disease ...r to the public in the lives of scientist Stephen ...ms Tuesdays with Morrie was written. , For most ...hy these people develop the disease, which causes ...
... the evening of April 17th, in Philadelphia, follo...cience and the spirit of discovery, nine individua...nd two will be presented with prestigious Bower Aw...ursor to the Nobel Prize, are awarded for outstand... impacted and enhanced the quality of human life a...
Other Biology News:Mantis shrimp vision reveals new way that animals can see 2Mantis shrimp vision reveals new way that animals can see 3Motor neuron disease and toxic substances: Possible link? 2Motor neuron disease and toxic substances: Possible link? 3Science and technology take center stage this election year 2Science and technology take center stage this election year 3Science and technology take center stage this election year 4Science and technology take center stage this election year 5Science and technology take center stage this election year 6
...ining method for labeling DNA breaks and total cel...try. The kit contains the instructions and reagen...ding; positive and negative control cells for asse...rinsing buffers for processing individual steps in...
ReadyPrep Overlay Agarose, 50 ml from Bio-Rad
Model 111 Mini IEF Cell, complete from Bio-Rad
...on features into a small-footprint design, Biomek ...utions. It puts every aspect of liquid handling i...grations into a single, automated system thats as...omical. The Biomek NX provides all this, while off...
Biology Products: